Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2014.11.490

Related search